

29. (Reiterated) The method of claim 26, wherein the prosaposin receptor agonist is selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2.
30. (Reiterated) The method of claim 26, wherein the contacting is *in vitro*.
31. (Reiterated) The method of claim 26, wherein the contacting is *in vivo*.

#### IN THE SPECIFICATION:

In the DETAILED DESCRIPTION OF THE INVENTION, page 11, line 10, after "sequence", please replace "LIRX<sub>1</sub>NNX<sub>2</sub>TX<sub>3</sub>X<sub>4</sub>X<sub>3</sub>X<sub>1</sub>X<sub>1</sub>" with "LIX<sub>1</sub>NNX<sub>2</sub>TX<sub>3</sub>X<sub>4</sub>X<sub>3</sub>X<sub>1</sub>X<sub>1</sub>" (SEQ ID NO: 25).

#### REMARKS

These amendments are made to correct a typographical error. No new matter is added. In transcribing the inventors notations, where "R" is an amino acid, to notation where "X" is an amino acid, the drafter unintentionally omitted a change from "R" to "X<sub>1</sub>". This unintentional omission resulted in a duplication of amino acids, "RX<sub>1</sub>".

Support for the amendments is found in the examples of "LIRX<sub>1</sub>NNX<sub>2</sub>TX<sub>3</sub>X<sub>4</sub>X<sub>3</sub>X<sub>1</sub>X<sub>1</sub>" provided in the DETAILED DESCRIPTION, page 11, lines 13 to 22. The examples are:

The prosaposin receptor agonist preferably contains the amino acid sequence Leu-Ile-Asp-Asn-Asn-Lys-Thr-Glu-Lys-Glu-Ile-Leu (SEQ ID NO:3), which corresponds to amino acids 18 to 29 of saposin C. More preferably, an active fragment of prosaposin has the amino acid sequence Cys-Glu-Phe-Leu-Val-Lys-Glu-Val-Thr-Lys-Leu-Ile-Asp-Asn-Asn-Lys-Thr-Glu-Lys-Glu-Ile-Leu (SEQ ID NO:1), which corresponds to amino acids 8 to 29 of saposin C, or the amino acid sequence Thr-D-Ala-Leu-Ile-Asp-Asn-Ala-Thr-Glu-Glu-Ile-Leu-Tyr (SEQ ID NO:2), which corresponds to amino acids 16 to 29 of saposin C but which has been modified by a D-alanine for lysine substitution at position 2; an alanine for lysine substitution at position 8; a deletion of lysine at position 11 and the addition of a C-terminal tyrosine residue (see TABLE 2).

As can be seen by inspection, SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 are not example of  $LIRX_1NNX_2TX_3X_4X_3X_1X_1$ . However, these SEQ ID NOS are examples of  $LIX_1NNX_2TX_3X_4X_3X_1X_1$ ,

Further support is found in TABLE 3, page 13, and the accompanying disclosure on page 12, lines 7 to 20. As can be seen by inspection, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, and SEQ ID NO:7 are not examples of  $LIRX_1NNX_2TX_3X_4X_3X_1X_1$ . However, these SEQ ID NOS are examples of  $LIX_1NNX_2TX_3X_4X_3X_1X_1$ .

Further support is found in TABLE 4, page 14, and the accompanying disclosure on page 13, lines 8 to 17, which discuss the "well-conserved adjacent asparagine residues, leucine residue and charged residues [which] can be important for the activity of an active fragment of prosaposin in alleviating neuropathic pain." As can be seen by inspection, SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10 are derivatives of  $LIX_1NNX_2TX_3X_4X_3X_1X_1$ . *Note*, the underlined amino acids in TABLE 4. However, these SEQ ID NOS are not derivatives of  $LIRX_1NNX_2TX_3X_4X_3X_1X_1$ .


Further support is found in the original claims 2, 11, 20, and 28. These claims all recite that  $LIRX_1NNX_2TX_3X_4X_3X_1X_1$  has the amino acid sequence shown in SEQ ID NO:2. As can be seen by inspection,  $LIRX_1NNX_2TX_3X_4X_3X_1X_1$  cannot have the amino acid sequence shown in SEQ ID NO:2. However,  $LIX_1NNX_2TX_3X_4X_3X_1X_1$  can have the amino acid sequence shown in SEQ ID NO:2.

If the Examiner would like to discuss any of the amendments, Applicant's representative can be reached at (619) 678-5070.

Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 12/22/97

  
John R. Wetherell, Jr., Ph.D.  
Reg. No. 31,678  
Attorney for Applicant

Fish & Richardson P.C.  
4225 Executive Square, Suite 1400  
La Jolla, CA 92037

Telephone: (619) 678-5070  
Facsimile: (619) 678-5099

45859.LJ1